Effect of sarpogrelate on angiographic luminal loss and clinical outcome after endovascular treatment for peripheral artery disease

Dong-A University Hospital0 个研究点目标入组 50 人开始时间: 待定最近更新: 2019年12月16日

适应症

试验速览

暂无简介。

•1. Patients with a newborn femoral artery lesion or a newborn knee-well (BTK) lesion with a greater than 50% stenosis;
•2. Successful completion of peripheral vascular (PTA) treatment with peripheral arterial vessels (Fontaine 2, 3) or severe inferior ischemia (CLI)
•3. Patients with at least 3 months of treatment after peripheral vascular treatment of antipsychotic - like aspirin + clopidogrel

•1. Under 18; over 85; over 85.
•2. For lesions of incoming arteries: Inflow lesion: aortoilliac arterial lesion
•3. In case of acute limb ischemia by thrombus
•4. In the case of taboos in administering anti-platelet drugs and with thrombocytopenia (<100,000/µL)
•5. Patient with liver cirrhosis of Child Class B and higher
•6. Patients with anticoagulants
•7. Severe heart failure (with a heart rate of less than 35% or NYHA 4)
•8. If you have recently developed cerebral infarction or myocardial infarction (within 6 months)
•9. Patients whose life expectancy is expected to be less than one year due to other conditions
•10. Pregnant women, pregnant or nursing mothers

发起方